科兴制药: 信息披露管理制度

Core Points - The document outlines the information disclosure management system of Sinovac Biotech Ltd, ensuring timely, accurate, and complete disclosure of significant information that may impact the trading price of the company's securities and investor decisions [2][3][4]. Group 1: General Principles - The information disclosure is a continuous responsibility of the company, requiring compliance with laws, regulations, and relevant rules [6][7]. - Information must be disclosed truthfully, accurately, and completely, avoiding misleading statements or omissions [7][8]. - All investors should receive disclosed information simultaneously, with no advance disclosure to any individual or entity [7][8]. Group 2: Disclosure Obligations - The company and its subsidiaries must adhere to the established disclosure regulations [3][4]. - Major events that could significantly affect the company's securities must be disclosed immediately [14][15]. - The company must disclose regular reports, including annual, semi-annual, and quarterly reports, within specified timeframes [21][22]. Group 3: Reporting Procedures - The internal process for handling undisclosed information begins when a significant event occurs or is anticipated [20]. - The board of directors must approve all periodic reports before disclosure [30][31]. - Any discrepancies between preliminary and final reports must be corrected promptly [12][28]. Group 4: Media and Communication - The company must use qualified media for disclosures, ensuring that information is not published in other media before it appears in the designated channels [48][49]. - The board secretary is responsible for coordinating and organizing the disclosure process, ensuring compliance with all regulations [50][51]. Group 5: Accountability and Compliance - Directors and senior management are accountable for the accuracy and completeness of disclosed information [64][65]. - Violations of disclosure obligations may result in disciplinary actions against responsible individuals [66][67]. - The company must review its disclosure practices following any regulatory penalties or criticisms [67][68].